Pollard, Samantha
Chan, Brandon
Gerrie, Alina S.
Raymakers, Adam J. N.
Regier, Dean A.
Funding for this research was provided by:
Genome Canada and Genome British Columbia (G05CHS, 271LYM)
Article History
Received: 2 June 2023
Accepted: 23 July 2024
First Online: 27 July 2024
Competing interests
: Samantha Pollard has received personal fees from Roche Canada, Bitota Economics Group, and AstraZeneca Canada, as co-director at IMPRINT Research Consulting Ltd outside the submitted work. Adam Raymakers reports currently serving as a member of the pan-Canadian Oncology Drug Review Expert Review Committee (pERC) within the Canadian Agency for Drugs and Technologies in Health (CADTH). Alina S Gerrie has received institutional research funding from Janssen, AstraZeneca, Abbvie, and Roche Canada, honoraria from Janssen, Astrazeneca, Abbvie, and Beigene, and has served as a clinical expert for CADTH. Dean A Regier has received travel funding from Illumina; his institution has received research funding for a project from Roche Canada. Brandon Chan has no competing interests to declare.